Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.780,35 +151,87 (+0,40%) EUR/USD
1,0726 -0,0007 (-0,06%) Bitcoin EUR
60.156,36 +230,73 (+0,39%) CMC Crypto 200
1.391,09 +8,51 (+0,62%)
Beam Therapeutics Inc. (BEAM)
Dopo ore:
| Chiusura precedente | 22,74 |
| Aperto | 22,00 |
| Denaro | 21,59 x 200 |
| Lettera | 21,68 x 100 |
| Min-Max giorno | 20,84 - 22,55 |
| Intervallo di 52 settimane | 16,95 - 49,50 |
| Volume | |
| Media Volume | 1.543.124 |
| Capitalizzazione | 1,872B |
| Beta (5 anni mensile) | 1,77 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,63 |
| Prossima data utili | 08 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 50,00 |
GlobeNewswireBeam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease ModelsCAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-302, to directly correct the PiZ mutation, the primary disease-causing muta
- GlobeNewswire
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therap
- GlobeNewswire
Beam Therapeutics to Participate in Upcoming September Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor conferences: Citi’s 18th Annual BioPharma Conference 2023 on Thursday, September 7, 2023 at 8:50 a.m. ET in Boston;2023 Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 at 10:15 a.m. ET
